Lung Neuroendocrine Carcinoma — Trials

Lung Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 389
Recruiting: 206
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (158)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07485920	A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer	not yet recruiting	Phase 4	20	The Affiliated Hospital of Qingdao UniversityOTHER	1	Mar 20, 2026	clinicaltrials
NCT06951841	Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction	not yet recruiting	Phase 4	31	China Medical University, China